Title:The Present Difficulties and Potential Benefits of Dopaminergic Agents in Parkinson's Disease Treatment
Volume: 12
Author(s): Shivendra Kumar*, Harsh Bharadwaj, Sunam Saha, Kuldeep Singh, Parshant Kumar, Swamita Arora, Deep Chandra*, Deepali Vij, Shilpa Srivastava, Kapil Gupta and Ashish Srivastava
Affiliation:
- Rajiv Academy for Pharmacy, Mathura, U.P. India
- F.S. University,
Shikohabad, Firozabad, U.P. India
Keywords:
Parkinson’s disease, dopaminergic agents, neurodegenerative disorder, substantia nigra, motor impairments, bradykinesia.
Abstract: Parkinson's disease (PD) is a progressive neurological condition characterized by bradykinesia,
rigidity, tremors, and impaired balance, among other motor impairments. The issue arises
from dopaminergic neurons located in the spinal column of the brain. This research report examines
the therapeutic potential of dopaminergic medications in the management of Parkinson's disease.
The central concept of Parkinson's disease (PD) revolves around the notion that dopaminergic
pathways exert significant influence over the regulation of movement. The book examines various
dopaminergic medications, elucidating their mechanisms of action and the impact they exert on dopamine
signaling. Examples of these medications include levodopa, dopamine agonists, and monoamine
oxidase-B (MAO-B) inhibitors. Although dopaminergic medicines initially aid in the treatment
of Parkinson's disease (PD), prolonged usage of these medications gives rise to several complications.
Experiencing dyskinesias and motor fluctuations, characterized by episodes of involuntary
movements and behaviors that are undesired, is a significant challenge. This study investigates
the underlying causes of these difficulties and explores potential treatment options, including the
use of controlled-release formulations and further therapy. The book discusses the non-motor symptoms
of Parkinson's disease (PD), as well as the use of dopaminergic medications to treat mood disorders,
autonomic dysfunction, and cognitive loss. Dopaminergic medications remain crucial in reducing
motor symptoms and enhancing the quality of life for those with Parkinson's disease. Parkinson's
disease (PD) is a complex condition with multiple distinct variations. In order to address its
existing challenges and explore its potential implications for future Parkinson's disease medications,
a comprehensive and effectively coordinated strategy is required.